Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: A double blind, randomized clinical trial

Minerva Endocrinologica

Volumn 37, Issue 2, 2012, Pages 195-200

  Zangiabadi, N ^a,b   Shafiee, K ^c   Alavi, K H ^b   Assadi, A R ^d   Damavandi, M ^e  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Afzal Research Center   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d University of Applied Science Technology of Kerman Welfare   (Iran)

^e Samen Diabetes Center   (Iran)

Author keywords

Atorvastatin; Diabetes mellitus; Electrophysiology; Polyneuropathies

Indexed keywords

ATORVASTATIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROPHYSIOLOGY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEURAL CONDUCTION; PYRROLES; RATS; TIBIAL NERVE;

EID: 84867298494     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alcocer L. Statins for everybody? New evidence on the efficacy and safety of the inhibitors of HMG Co-A reductase. Am J Ther 2003;10:423-8.
2. Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A 3rd et al. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010;41:426-30.
3. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001;113-9. (Pubitemid 32453167)
4. Allan H, Ropper RHB. Adams and victors principles of neurology. 8 ed. 2005.
5. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000;36:410-6. (Pubitemid 30624000)
6. Collidge TA, Razvi S, Nolan C, Whittle M, Stirling C, Russell AJ et al. Severe statin-induced rhabdomyolysis mimicking Guillain-Barre syndrome in four patients with diabetes mellitus treated with fusidic acid. Diabet Med 2010;27:696-700.
7. No authors listed]. Peripheral neuropathy and statins. Prescrire Int 2007;16:247-8.
8. Vaughan TB, Bell DS. Statin neuropathy masquerading as diabetic autoimmune polyneuropathy. Diabetes Care 2005;28:2082. (Pubitemid 41060997)
9. Hamilton SJ, Chew GT, and Watts GF. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009;32:810-2.
10. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 2003;37:274-8. (Pubitemid 36172871)
11. de Langen JJ and van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med 2006;64:334-8. (Pubitemid 44614418)
12. Gaist D, García Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;50:931-3. (Pubitemid 33788572)
13. Gaist D, Jeppesen U, Andersen M, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7. (Pubitemid 34507158)
14. Arezzo JC and Zotova E. Electrophysiologic measures of diabetic neuropathy: mechanism and meaning. Int Rev Neurobiol 2002;50:229-55.
15. Ohgaki K, Nakano K, Shigeta H, Kitagawa Y, Nakamura N, Iwamoto K et al. Ratio of motor nerve conduction velocity to F-wave conduction velocity in diabetic neuropathy. Diabetes Care 1998;21:615-8. (Pubitemid 28172944)
16. Ali TK, Al-Gayyar MM, Matragoon S, Pillai BA, Abdelsaid MA, Nussbaum JJ et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 2011;54:657-68.
17. Camera A, Hopps E, Caimi G. Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects. Minerva Endocrinol 2007;32:209-29.
18. Honjo M, Tanihara H, Nishijima K, Kiryu J, Honda Y, Yue BY et al. Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol 2002;120:1707-13. (Pubitemid 36401807)
19. Daimon M, Aomi S, Kawamata T, Kurosawa H. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus. Neurosci Lett 2004;362:122-6. (Pubitemid 38759082)
20. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 2003;61:S35-9. (Pubitemid 36918320)
21. Ii M, Nishimura H, Kusano KF, Qin G, Yoon YS, Wecker A et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93-102. (Pubitemid 40962574)
22. Nouri M, Pourabbasi A, Ebrahimnejad M, Abolhassani F, Jahanzad I. Pravastatin prevents ischemia-reperfusion injury in rat sciatic nerve. Surg Neurol 2006;66:337-8; discussion 338-40.
23. Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. Muscle Nerve 2004;30:663-6. (Pubitemid 39447292)
24. Liu MS, Hu BL, Cui LY, Tang XF, Du H, Li BH. Clinical and neurophysiology features of 700 patients with diabetic peripheral neuropathy. Zhonghua Nei Ke Za Zhi 2005;44:173-6.